Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 537-542

  Kollmannsberger, Christian ^a   Daneshmand, Siamak ^a   So, Alan ^a   Chi, Kim N ^a   Murray, Nevin ^a   Moore, Christie ^a   Hayes Lattin, Brandon ^a   Nichols, Craig R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISSEMINATED CANCER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; TERATOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; TESTIS TUMOR; THORAX RADIOGRAPHY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOGRAPHY, THORACIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TERATOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77449108828     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.0755     Document Type: Article

References (25)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990 (Pubitemid 20382338)
2. Groll RJ, Warde P, Jewett MA: A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 64:182-197, 2007 (Pubitemid 350026782)
3. Warde P, Gospodarowicz MK, Banerjee D, et al: Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157: 1705-1709, 1997
4. Christensen D: The Will Rogers phenomenon: Roping the effects of a new cancer staging system. J Natl Cancer Inst 95:1105-1106, 2003
5. Mead G: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
6. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007
7. van Dijk MR, Steyerberg EW, Habbema JD: Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 42: 820-826, 2006
8. Albers P, Siener R, Krege S, et al: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966-2972, 2008
9. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 25:5597-5602, 2007
10. Albers P, Weissbach L, Krege S, et al: Predictions of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171:1835-1838, 2004
11. Borge N, Fossa SD, Ous S, et al: Late recurrence of testicular cancer. J Clin Oncol 6:1248-1253, 1988
12. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995
13. Gerl A, Clemm C, Schmeller N, et al: Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8:41-47, 1997 (Pubitemid 27112801)
14. Ravi R, Oliver RT, Ong J, et al: A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol 80:647-652, 1997 (Pubitemid 28316392)
15. Shahidi M, Norman AR, Dearnaley DP, et al: Late recurrence in 1263 men with testicular germ cell tumors: Multivariate analysis of risk factors and implications for management. Cancer 95:520-530, 2002 (Pubitemid 34810177)
16. Ronnen EA, Kondagunta GV, Bacik J, et al: Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 23: 6999-7004, 2005 (Pubitemid 46260286)
17. Oldenburg J, Alfsen GC, Waehre H, et al: Late recurrences of germ cell malignancies: A population-based experience over three decades. Br J Cancer 94:820-827, 2006
18. Sheinfeld J: Risks of the uncontrolled retroperitoneum. Ann Surg Oncol 10:100-101, 2003
19. Tandstad T, Olav D, Cohn-Cedermark G, et al: Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA Management Program. J Clin Oncol 27:2122-2128, 2009
20. Debono DJ, Heilman DK, Einhorn LH, et al: Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455-1464, 1997
21. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
22. Loehrer-PJ S, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
23. de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837-1843, 1997
24. Saxman SB, Finch D, Gonin R, et al: Longterm follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 16:702-706, 1998 (Pubitemid 28135618)
25. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 53:497-513, 2008